Lifesci Capital Analyst Recommendations & Stock Picks

→ [Urgent] Protect your money before November (From Weiss Ratings) (Ad)

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Lifesci Capital. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Lifesci Capital.

Country All Countries

• United States(NYSE & NASDAQ)
• United States(All Exchanges)
• Canada
• United Kingdom

Sector All Sectors

• Aerospace
• Auto/Tires/Trucks
• Basic Materials
• Business Services
• Computer and Technology
• Construction
• Consumer Discretionary
• Consumer Goods
• Consumer Staples
• Finance
• Industrial Products
• Medical
• Miscellaneous
• Multi-Sector Conglomerates
• Oils/Energy
• Retail/Wholesale
• Services
• Transportation
• Utilities

All Market Caps Large Cap ($10B+) Medium Cap ($2B-$10B) Small Cap (<$2B) Market Cap

MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription

MarketRank™Upgrade to All Access to use the All Ranks Filter

Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription

Media SentimentUpgrade to All Access to use the All Sentiments Filter

Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription

Analyst ConsensusUpgrade to All Access to use the All Ratings Filter

Export to Excel

Company	Current Price	Rating Date	Action	Brokerage	Analyst	Rating	Price Target	Impact on Price	Details	Actions
DNTH Dianthus Therapeutics	$24.88 -1.5%	6/11/2024	Upgraded by	Lifesci Capital	Analyst R. Katkhuda	Strong-Buy		Low	View details for Lifesci Capital rating of Dianthus Therapeutics (NASDAQ:DNTH) on 6/11/2024
CALT Calliditas Therapeutics AB (publ)	$39.05 +0.3%	5/28/2024	Downgraded by	Lifesci Capital	Analyst R. Katkhuda	Strong-Buy -> Hold		Low	View details for Lifesci Capital rating of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) on 5/28/2024
CATX Perspective Therapeutics	$11.93 +15.4%	5/6/2024	Reiterated by	Lifesci Capital	Analyst A. Dhankher	Outperform		N/A	View details for Lifesci Capital rating of Perspective Therapeutics (NYSE:CATX) on 5/6/2024
MLYS Mineralys Therapeutics	$11.79 -3.4%	3/26/2024	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Low	View details for Lifesci Capital rating of Mineralys Therapeutics (NASDAQ:MLYS) on 3/26/2024
GPCR Structure Therapeutics	$47.52 -2.2%	2/27/2024	Reiterated by	Lifesci Capital	Analyst M. Belghiti	Outperform		Low	View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 2/27/2024
VTYX Ventyx Biosciences	$2.75	2/28/2024	Upgraded by	Lifesci Capital	Analyst S. Slutsky	Market Perform -> Outperform		Low	View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 2/28/2024
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
LRMR Larimar Therapeutics	$7.87 -1.5%	2/20/2024	Reiterated by	Lifesci Capital	Analyst C. Jubinville	Outperform		Low	View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/20/2024
INBX Inhibrx	$14.57 +2.7%	1/23/2024	Downgraded by	Lifesci Capital	Analyst S. Slutsky	Outperform -> Market Perform		Low	View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 1/23/2024
IVA Inventiva	$2.70 +1.1%	1/5/2024	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Low	View details for Lifesci Capital rating of Inventiva (NASDAQ:IVA) on 1/5/2024
TARS Tarsus Pharmaceuticals	$27.28 -5.4%	12/26/2023	Reiterated by	Lifesci Capital	Analyst C. Jubinville	Outperform		Low	View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 12/26/2023
RCKT Rocket Pharmaceuticals	$20.68 -2.5%	12/26/2023	Reiterated by	Lifesci Capital	Analyst C. Jubinville	Outperform		Low	View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/26/2023
SYRE Spyre Therapeutics	$25.79 +1.4%	12/4/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of Spyre Therapeutics (NASDAQ:SYRE) on 12/4/2023
TCRX TScan Therapeutics	$6.94 -6.7%	11/27/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of TScan Therapeutics (NASDAQ:TCRX) on 11/27/2023
VTYX Ventyx Biosciences	$2.75	11/7/2023	Downgraded by	Lifesci Capital	Analyst S. Slutsky	Outperform -> Market Perform		Low	View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/7/2023
VERV Verve Therapeutics	$5.10 -3.2%	8/8/2023	Reiterated by	Lifesci Capital	Analyst C. Jubinville	Outperform		Low	View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 8/8/2023
INBX Inhibrx	$14.57 +2.7%	8/8/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 8/8/2023
TNYA Tenaya Therapeutics	$3.16 -4.2%	8/8/2023	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low	View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/8/2023
PYXS Pyxis Oncology	$3.42 -6.6%	4/26/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 4/26/2023
OLMA Olema Pharmaceuticals	$12.00 +1.1%	4/26/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 4/26/2023
INBX Inhibrx	$14.57 +2.7%	4/26/2023	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low	View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 4/26/2023
AVDL Avadel Pharmaceuticals	$15.60 -0.6%	4/26/2023	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low	View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 4/26/2023
ALXO ALX Oncology	$6.93 -6.1%	4/26/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 4/26/2023
IRON Disc Medicine	$43.54 -2.9%	4/24/2023	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Low	View details for Lifesci Capital rating of Disc Medicine (NASDAQ:IRON) on 4/24/2023
BLU BELLUS Health	C$19.48 -0.1%	4/18/2023	Downgraded by	Lifesci Capital	Analyst S. Slutsky	Outperform -> Market Perform		N/A	View details for Lifesci Capital rating of BELLUS Health (TSE:BLU) on 4/18/2023
AKRO Akero Therapeutics	$22.16 -3.3%	4/11/2023	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low	View details for Lifesci Capital rating of Akero Therapeutics (NASDAQ:AKRO) on 4/11/2023
IFRX InflaRx	$1.46 -3.3%	4/5/2023	Upgraded by	Lifesci Capital	-	Market Perform -> Outperform		Low	View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 4/5/2023
CRNX Crinetics Pharmaceuticals	$44.29 -0.9%	3/27/2023	Reiterated by	Lifesci Capital	Analyst C. Jubinville	Outperform		Low	View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 3/27/2023
OBIO Orchestra BioMed	$7.44 -7.5%	3/8/2023	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		Low	View details for Lifesci Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 3/8/2023
ELVN Enliven Therapeutics	$20.47 -5.1%	3/7/2023	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of Enliven Therapeutics (NASDAQ:ELVN) on 3/7/2023
MLTX MoonLake Immunotherapeutics	$39.49 -1.7%	12/21/2022	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		N/A	View details for Lifesci Capital rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 12/21/2022
PYXS Pyxis Oncology	$3.42 -6.6%	12/1/2022	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Low	View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 12/1/2022
ATXS Astria Therapeutics	$8.99 +1.8%	11/28/2022	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of Astria Therapeutics (NASDAQ:ATXS) on 11/28/2022
ALXO ALX Oncology	$6.93 -6.1%	11/8/2022	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Low	View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/8/2022
AKLI Akili	$0.43	9/6/2022	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		Low	View details for Lifesci Capital rating of Akili (NASDAQ:AKLI) on 9/6/2022
VYNE VYNE Therapeutics	$2.21 -6.4%	8/12/2022	Downgraded by	Lifesci Capital	Analyst P. Dolezal	Outperform -> Market Perform		Low	View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 8/12/2022
LRMR Larimar Therapeutics	$7.87 -1.5%	8/12/2022	Upgraded by	Lifesci Capital	Analyst P. Dolezal	Market Perform -> Outperform		Low	View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/12/2022
TNYA Tenaya Therapeutics	$3.16 -4.2%	6/16/2022	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low	View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 6/16/2022
VERA Vera Therapeutics	$35.53 -0.5%	3/28/2022	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Low	View details for Lifesci Capital rating of Vera Therapeutics (NASDAQ:VERA) on 3/28/2022
ELDN Eledon Pharmaceuticals	$2.61 -7.4%	3/25/2022	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Medium	View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/25/2022
LRMR Larimar Therapeutics	$7.87 -1.5%	2/16/2022	Downgraded by	Lifesci Capital	Analyst Patrick Dolezal	Outperform -> Market Perform	$3.00	Medium	View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/16/2022
Kiss of death from Joe Biden (Ad) Biden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election. I have uncovered a bombshell that changes everything… and threatens everything.
VERV Verve Therapeutics	$5.10 -3.2%	12/22/2021	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		High	View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 12/22/2021
ALLK Allakos	$1.12 -4.3%	12/22/2021	Downgraded by	Lifesci Capital	Analyst S. Slutsky	Outperform -> Market Perform		High	View details for Lifesci Capital rating of Allakos (NASDAQ:ALLK) on 12/22/2021
NNOX Nano-X Imaging	$7.23 -4.1%	11/17/2021	Downgraded by	Lifesci Capital	Analyst R. Rakhit	Outperform -> Market Perform		Low	View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 11/17/2021
VTYX Ventyx Biosciences	$2.75	11/15/2021	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		High	View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/15/2021
ALXO ALX Oncology	$6.93 -6.1%	11/4/2021	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Medium	View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/4/2021
PYXS Pyxis Oncology	$3.42 -6.6%	11/2/2021	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Low	View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 11/2/2021
RCKT Rocket Pharmaceuticals	$20.68 -2.5%	10/24/2021	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low	View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/24/2021
DRIO DarioHealth	$1.10 -6.0%	8/26/2021	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		High	View details for Lifesci Capital rating of DarioHealth (NASDAQ:DRIO) on 8/26/2021
VRDN Viridian Therapeutics	$12.18 -0.2%	8/24/2021	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		Low	View details for Lifesci Capital rating of Viridian Therapeutics (NASDAQ:VRDN) on 8/24/2021
LRMR Larimar Therapeutics	$7.87 -1.5%	8/4/2021	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Medium	View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/4/2021
OLMA Olema Pharmaceuticals	$12.00 +1.1%	6/21/2021	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		High	View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 6/21/2021
NNOX Nano-X Imaging	$7.23 -4.1%	6/3/2021	Reiterated by	Lifesci Capital	Analyst R. Rakhit	Outperform		High	View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 6/3/2021
ADVM Adverum Biotechnologies	$6.59 -10.0%	4/29/2021	Downgraded by	Lifesci Capital	Analyst P. Dolezal	Outperform -> Market Perform		High	View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 4/29/2021
ELDN Eledon Pharmaceuticals	$2.61 -7.4%	3/18/2021	Reiterated by	Lifesci Capital	Analyst R. Katkhuda	Outperform		High	View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/18/2021
COGT Cogent Biosciences	$8.50 -3.4%	1/4/2021	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		N/A	View details for Lifesci Capital rating of Cogent Biosciences (NASDAQ:COGT) on 1/4/2021
CLDX Celldex Therapeutics	$34.66 -0.7%	11/17/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		High	View details for Lifesci Capital rating of Celldex Therapeutics (NASDAQ:CLDX) on 11/17/2020
BLU BELLUS Health	C$19.48 -0.1%	11/12/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		N/A	View details for Lifesci Capital rating of BELLUS Health (TSE:BLU) on 11/12/2020
TARS Tarsus Pharmaceuticals	$27.28 -5.4%	11/10/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Medium	View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 11/10/2020
AVDL Avadel Pharmaceuticals	$15.60 -0.6%	11/9/2020	Reiterated by	Lifesci Capital	Analyst D. Sherman	Outperform		Low	View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 11/9/2020
ADVM Adverum Biotechnologies	$6.59 -10.0%	11/5/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Medium	View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 11/5/2020
IFRX InflaRx	$1.46 -3.3%	10/30/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Market Perform		Low	View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 10/30/2020
ALLK Allakos	$1.12 -4.3%	10/22/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		Low	View details for Lifesci Capital rating of Allakos (NASDAQ:ALLK) on 10/22/2020
MEIP MEI Pharma	$2.82 -2.1%	10/21/2020	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Medium	View details for Lifesci Capital rating of MEI Pharma (NASDAQ:MEIP) on 10/21/2020
RCKT Rocket Pharmaceuticals	$20.68 -2.5%	10/16/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		Low	View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/16/2020
INBX Inhibrx	$14.57 +2.7%	10/15/2020	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Medium	View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 10/15/2020
IMVT Immunovant	$26.19 -2.3%	10/6/2020	Reiterated by	Lifesci Capital	Analyst S. Slutsky	Outperform		High	View details for Lifesci Capital rating of Immunovant (NASDAQ:IMVT) on 10/6/2020
VYNE VYNE Therapeutics	$2.21 -6.4%	10/2/2020	Reiterated by	Lifesci Capital	Analyst P. Dolezal	Outperform		High	View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 10/2/2020
ALXO ALX Oncology	$6.93 -6.1%	9/30/2020	Reiterated by	Lifesci Capital	Analyst A. Evertts	Outperform		Low	View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 9/30/2020
CRTX Cortexyme	$0.68 -4.2%	9/24/2020	Reiterated by	Lifesci Capital	Analyst D. Sherman	Outperform		High	View details for Lifesci Capital rating of Cortexyme (NASDAQ:CRTX) on 9/24/2020

MarketBeat Community Rating for Lifesci Capital

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.